Abstract: An information display device includes a display unit configured to display information about an object such that the information about the object at least partially overlaps with forward view of a user, and a controller configured to control display of the display unit. The controller is configured to estimate or acquire a prospective moving direction of the object, acquire a sight-line frequency representing a frequency with which a sight-line of the user is directed to the object within a prescribed period, determine whether the sight-line frequency is equal to or more than a prescribed frequency threshold, and cause the display unit to display the prospective moving direction of the object at least on condition that the controller determines that the sight-line frequency is less than the frequency threshold.

Abstract: Provided is a magnetic recording medium capable of ensuring good electromagnetic conversion characteristics while suppressing an increase in a standard deviation ?PES due to traveling many times. The magnetic recording medium sequentially includes a base, an underlayer, and a magnetic layer. The magnetic layer includes magnetic particles, conductive first particles, and second particles having a Mohs hardness of 7.0 or more. The magnetic layer has a concavoconvex shape on a magnetic surface, and the concavoconvex shape includes a first protrusion including the first particles and a second protrusion including the second particles. A ratio H1/H2 of an average height H1 of the first protrusion and an average height H2 of the second protrusion satisfies H1/H2?2.3, a height range ?H obtained from statistical information on a height of the concavoconvex shape satisfies 3.00 nm??H?6.00 nm, and a gradient range ?A obtained from statistical information on a gradient of the concavoconvex shape satisfies 4.

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

Abstract: An object is to provide a magnetic recording medium excellent in an electromagnetic conversion characteristic and traveling performance. The present technology provides a magnetic recording medium including a magnetic layer containing a magnetic powder, the magnetic recording medium having an average magnetic cluster size of 1850 nm2 or less, the average magnetic cluster size measured on the basis of an MFM image of a surface on a side of the magnetic layer, the magnetic layer containing first particles having conductivity and second particles having a Mohs hardness of 7 or more, in which protrusions are formed by the first particles and protrusions are formed by the second particles on the surface on the side of the magnetic layer, and a ratio (H1/H2) of an average height H1 of the protrusions formed by the first particles to an average height H2 of the protrusions formed by the second particles is 2.00 or less.

Abstract: A magnetic recording medium is a magnetic recording medium in the form of a tape and includes a substrate, a foundation layer provided on the substrate, and a magnetic layer provided on the foundation layer and containing a magnetic powder. The foundation layer and the magnetic layer each contain a lubricant. A squareness ratio of the magnetic layer in a perpendicular direction is equal to or higher than 65%, an average thickness of the magnetic recording medium is equal to or smaller than 5.6 ?m, a plurality of recessed portions each having a depth corresponding to 20% or higher of the average thickness of the magnetic layer is provided on a surface of the magnetic layer, and the number of the recessed portions per unit area of 1,600 ?m2 of the surface of the magnetic layer is equal to or greater than 20 and equal to or smaller than 200, and an amount of exudation of the lubricant per unit region of 12.5 ?m×9.3 ?m on the surface of the magnetic layer in a vacuum is equal to or greater than 3.

Abstract: According to one embodiment, a medical information processing apparatus includes processing circuitry. The processing circuitry acquires first and second medical images acquired in at least first and second time phases. The processing circuitry inputs the first and second medical images into a gene mutation classification model to generate first and second gene mutation classification results. The processing circuitry judges consistency of the gene mutation classification model based on the first and second gene mutation classification results.

Abstract: A drive assistance system includes a display object configurator that sets, as a display object or a non-display object, each of traffic participants recognized as alert objects from among nearby traffic participants, and a display controller that performs highlight image processing for highlighting the presence of the display object. When a first traffic participant set as the display object and a second traffic participant set as the non-display object are present in the vicinity of the subject vehicle and recognized as alert objects with the recognition of the first traffic participant by the driver being detected while the highlight image processing is performed, the display object configurator compares the degrees of influence of the first and second traffic participants, sets, as the display object, one of the first and second traffic participants designated on the basis of a result of the comparison, and sets the other as the non-display object.

Abstract: A method of producing a diffraction grating of borosilicate glass or barium borosilicate glass, the method comprising the steps of forming a grating on a surface of a silicon wafer the grating through the Bosch process; forming an oxide film on a surface of the grating by heating and exposure to water vapor of the silicon wafer; removing the oxide film using hydrofluoric acid; making the surface provided with the grating of the silicon wafer and a surface of a glass plate undergo anodic bonding; heating the silicon wafer and the glass plate bonded to each other; polishing a surface opposite to the boded surface of the silicon wafer and a surface opposite to the boded surface of the glass plate; and removing silicon from the glass plate by selective etching using xenon difluoride.

Abstract: Provided is a film for application to a 3D sample, the film including a photoresist layer that has alignment or direction marks thereon. After the fine pattern of the photoresist layer or coat is exposed, the photoresist layer is applied to a desired position of the 3D sample by aligning the alignment or direction marks of the film with alignment or direction marks on the 3D sample. This allows for transfer of an appropriate fine pattern. Part or all of the thickness or area of the photoresist layer is developed to form projections or depressions in the photoresist layer before the film is applied to the 3D sample.

Abstract: The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

Abstract: The present invention provides a compound having a glucosylceramide synthase inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of lysosomal storage diseases (e.g., Gaucher's disease, Fabry's disease, GM1-gangliosidosis, GM2 activator deficiency, Tay-Sachs disease, Sandhoffs disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

Abstract: The present invention provides a compound having a glucosylceramide synthase inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of lysosomal storage diseases (e.g., Gaucher's disease, Fabry's disease, GM1-gangliosidosis, GM2 activator deficiency, Tay-Sachs disease, Sandhoffs disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

Abstract: The present disclosure provides a wafer inspection technology that involves less degradation of the image quality even when an object to be observed has a variation in height due to warpage, etc. of a wafer. This wafer inspection apparatus obtains an image with less degradation by: adjusting the focal point of an observation optical system to a height measured by a height sensor for measuring wafer surface heights; and further, correcting a switching signal for a CCD line sensor on the basis of stage position data and optical magnification data corresponding to the height so as to make a correction corresponding to the wafer surface height.

Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

Abstract: A resin composition including (A) an epoxy resin, (B) a curing agent, and (C) an inorganic filler, in which a chloride ion content included in the resin composition measured in accordance with a sample combustion ion chromatography method (BS EN 14532 2007) is 50 ppm or less.

Abstract: The present disclosure provides a wafer inspection technology that involves less degradation of the image quality even when an object to be observed has a variation in height due to warpage, etc. of a wafer. This wafer inspection apparatus obtains an image with less degradation by: adjusting the focal point of an observation optical system to a height measured by a height sensor for measuring wafer surface heights; and further, correcting a switching signal for a CCD line sensor on the basis of stage position data and optical magnification data corresponding to the height so as to make a correction corresponding to the wafer surface height.

Abstract: The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I) wherein each symbol is as described in the specification, or a salt thereof.

Abstract: Resin compositions including (A) an epoxy resin, (B) a curing agent, and (C) an inorganic filler, in which a chloride ion content included in the resin composition measured in accordance with a sample combustion ion chromatography method (BS EN 14582 2007) is 50 ppm or less are capable of forming a cured product having excellent adhesion with a conductive layer even after the HAST test.

Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of central nervous system diseases including neurodegenerative disease, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.